[go: up one dir, main page]

AR043143A1 - Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico - Google Patents

Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico

Info

Publication number
AR043143A1
AR043143A1 ARP040100410A ARP040100410A AR043143A1 AR 043143 A1 AR043143 A1 AR 043143A1 AR P040100410 A ARP040100410 A AR P040100410A AR P040100410 A ARP040100410 A AR P040100410A AR 043143 A1 AR043143 A1 AR 043143A1
Authority
AR
Argentina
Prior art keywords
hydraphy
therapeutic agent
sildenafil citrate
crystal variety
crystal
Prior art date
Application number
ARP040100410A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303097A external-priority patent/GB0303097D0/en
Priority claimed from GB0321309A external-priority patent/GB0321309D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR043143A1 publication Critical patent/AR043143A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una forma sólida de citrato de sildenafilo en la que la relación de sildenafilo: citrato es de 1:0,5. También se conoce como: 1-[[3-(6,7-dihidro-1-metil-7-oxo-3-propil-1H-pirazolo[4,3-d]pirimidir-5-il)-4-etoxifenil]sulfonil]-4-metilpiperazina.
ARP040100410A 2003-02-11 2004-02-10 Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico AR043143A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0303097A GB0303097D0 (en) 2003-02-11 2003-02-11 Crystalline therapeutic agent
GB0321309A GB0321309D0 (en) 2003-09-11 2003-09-11 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
AR043143A1 true AR043143A1 (es) 2005-07-20

Family

ID=32870944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100410A AR043143A1 (es) 2003-02-11 2004-02-10 Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico

Country Status (3)

Country Link
AR (1) AR043143A1 (es)
TW (1) TW200500068A (es)
WO (1) WO2004072079A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
EP1633364B1 (en) 2004-01-05 2008-02-27 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
EP2366393B1 (en) 2005-04-19 2013-08-07 Takeda GmbH Roflumilast for the treatment of pulmonary hypertension
CN104940154A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种治疗泌尿外科疾病的药物枸橼酸西地那非组合物片剂
CN104940166A (zh) * 2015-07-23 2015-09-30 青岛蓝盛洋医药生物科技有限责任公司 一种治疗男性阳痿的药物枸橼酸西地那非组合物胶囊
CN105147690A (zh) * 2015-09-28 2015-12-16 青岛华之草医药科技有限公司 一种治疗泌尿外科类疾病的药物枸橼酸西地那非组合物片剂
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
WO2022178000A1 (en) * 2021-02-18 2022-08-25 Praxis Precision Medicines, Inc. Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
AU7269001A (en) * 2000-07-28 2002-02-13 Harris Laurence James Crystalline therapeutic agent
US6420557B1 (en) * 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent

Also Published As

Publication number Publication date
WO2004072079A1 (en) 2004-08-26
TW200500068A (en) 2005-01-01

Similar Documents

Publication Publication Date Title
UY28258A1 (es) Tratamiento terapeutico
ATE387450T1 (de) Meso-substituierte porphyrine
IL220759A0 (en) 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS , PHARMACEUTICEL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE MANUFACTURE OF MESICAMENTS
DE602004021585D1 (de) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
WO2005102396A3 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
AR030245A1 (es) Composiciones de gel que contienen metronidazol
SG145701A1 (en) Piperazine derivatives and their use as therapeutic agents
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
SE0301653D0 (sv) Novel compounds
ATE527242T1 (de) Piperazin derivate und deren anwendung als therapeutische wirkstoffe
EP1991055A4 (en) FORMULATIONS CONTAINING NON-OXIDIZING BIOCID AND ACTIVE HALOGEN SOURCE AND USE THEREOF FOR THE TREATMENT OF WATER
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ECSP055703A (es) POLIMORFO NOVEDOSO DEL N-METIL-N-(3-{3-[2-TIENILCARBONIL]-PIRAZOL-[1,5-a]-PIRIMIDINA-7-YL}FENIL)ACETAMIDA Y COMPUESTOS Y METODOS RELACIONADOS
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
AR043143A1 (es) Variedad cristalina de hemi-citrato de sildenafilo hidratado y su uso como agente terapeutico
MEP39608A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
UY29952A1 (es) Composiciones faramacéuticas que comprenden 4-(4-fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-7-(3-(pirrolidin-1-il)propoxi)quinazolina o una sal farmacéuticamente aceptable del mismo, procesos de preparación y uso
ATE432710T1 (de) Pharmazeutische zusammensetzungen, die diaminooxidase enthalten
ITRM20030194A0 (it) Uso di derivati del 7-nitro-2,1,3-benzossadiazolo per la terapia di forme tumorali.
BR0210632A (pt) Tratamento de doença parasìtica
ATE399532T1 (de) Medizinische seife
EA200600573A1 (ru) Активаторы плазминогена, имеющие сниженную способность связывать лизин

Legal Events

Date Code Title Description
FB Suspension of granting procedure